Literature DB >> 3145526

Pharmacological characterization of the physostigmine stimulus in rats.

M Jung1, A Perio, P Worms, P Soubrie.   

Abstract

Rats were trained to discriminate 0.10 mg/kg SC physostigmine from saline in a two-lever food-reinforced task. There was generalization to the acetylcholine esterase inhibitor THA as well as to the muscarinic receptor agonists arecoline, oxotremorine and RS 86, but not to neostigmine or nicotine. The physostigmine cue was blocked by SC scopolamine hydrobromide and by ICV pirenzepine, but not by scopolamine methylbromide or by mecamylamine. These antagonism studies suggest that the discriminative cue elicited by physostigmine might be mainly mediated by central M1 receptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3145526     DOI: 10.1007/bf00172975

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  10 in total

1.  Discriminable effects of antimuscarinics: dose response and substitution test studies.

Authors:  D A Overton
Journal:  Pharmacol Biochem Behav       Date:  1977-06       Impact factor: 3.533

2.  Solubilization and characterization of high and low affinity pirenzepine binding sites from rat cerebral cortex.

Authors:  C P Berrie; N J Birdsall; E C Hulme; M Keen; J M Stockton
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

3.  Comparison of the degree of discriminability of various drugs using the T-maze drug discrimination paradigm.

Authors:  D A Overton
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

4.  Physostigmine as a discriminative cue in rats.

Authors:  J O Johansson; T U Järbe
Journal:  Arch Int Pharmacodyn Ther       Date:  1976-01

5.  Effects of intracerebroventricular pirenzepine on muscarinic discriminations in rats.

Authors:  M Jung; A Perio; J P Terranova; P Worms; K Biziere
Journal:  Eur J Pharmacol       Date:  1987-07-02       Impact factor: 4.432

6.  The pharmacological assessment of RS 86 (2-ethyl-8-methyl-2,8-diazaspiro-[4,5]-decan-1,3-dion hydrobromide). A potent, specific muscarinic acetylcholine receptor agonist.

Authors:  J M Palacios; G Bolliger; A Closse; A Enz; G Gmelin; J Malanowski
Journal:  Eur J Pharmacol       Date:  1986-06-05       Impact factor: 4.432

7.  Characterization of the receptor mediating the nicotine discriminative stimulus.

Authors:  C Romano; A Goldstein; N P Jewell
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

8.  Role of training dose in discrimination of nicotine and related compounds by rats.

Authors:  I P Stolerman; H S Garcha; J A Pratt; R Kumar
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Discriminative stimulus properties of arecoline: a new approach for studying central muscarinic receptors.

Authors:  L T Meltzer; J A Rosecrans
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Discriminative stimulus properties of muscarinic agonists.

Authors:  M Jung; L Costa; G T Shearman; P H Kelly
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

  10 in total
  4 in total

Review 1.  Neuropharmacology of the interoceptive stimulus properties of nicotine.

Authors:  Thomas E Wooters; Rick A Bevins; Michael T Bardo
Journal:  Curr Drug Abuse Rev       Date:  2009-09

2.  Nicotine-like discriminative stimulus effects of acetylcholinesterase inhibitors and a muscarinic receptor agonist in Rhesus monkeys.

Authors:  Megan J Moerke; Lance R McMahon
Journal:  Drug Dev Ind Pharm       Date:  2019-02-22       Impact factor: 3.225

3.  Sexually diergic hypothalamic-pituitary-adrenal axis responses to selective and non-selective muscarinic antagonists prior to cholinergic stimulation by physostigmine in rats.

Authors:  Marissa A Smail; Jessica L Soles; Tracy E Karwoski; Robert T Rubin; Michael E Rhodes
Journal:  Brain Res Bull       Date:  2017-11-07       Impact factor: 4.077

Review 4.  More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.

Authors:  M J Moerke; L R McMahon; J L Wilkerson
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.